AU

Nuo Therapeutics IncOOTC AURX Stock Report

Last reporting period 30 Jun, 2024

Updated 11 Nov, 2024

Last price

Market cap $B

0.017

Micro

Exchange

OOTC - OTC

AURX Stock Analysis

AU

Uncovered

Nuo Therapeutics Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

17/100

Low score

Market cap $B

0.017

Dividend yield

Shares outstanding

41.799 B

Nuo Therapeutics, Inc. engages in the development and sale of biomedical products for chronic wound care. The company is headquartered in Houston, Texas. The company went IPO on 2017-01-19. The firm's Aurix System is a biodynamic hematogel, which harnesses a patient's innate regenerative abilities for the management of a variety of wounds. The firm commercialize cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The firm's commercial offering consists of a point of care technology for the safe and effective separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix, which produces a platelet rich plasma (PRP) gel at the point of care using the patient's own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.

View Section: Eyestock Rating